Image Of 5 mg Package Label (3952)
Aricept
Product Images NDC 54868-3952
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Aricept (NDC 54868-3952). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image Of 10 mg Package Label (4245)
Aricept-01 (Aricept 01)
Aricept-02 (Aricept 02)
This text appears to be a table containing data on clinical improvement of patients taking different dosages of Aricept as compared to Placebo. The table lists the mean scores on the ADAS-cog measurement scale at baseline and after several weeks of drug treatment. It seems to be useful for clinicians and researchers studying the efficacy of Aricept in improving cognitive function.*
Aricept-03 (Aricept 03)
The text appears to be a table showing the change in ADAS-cog score and the cumulative percentage of patients in different treatment groups (Aricept 10mg/day, Aricept 5mg/day, and Placebo). The data suggests that patients in the Aricept 10mg/day group showed the most improvement in ADAS-cog score, with a cumulative percentage of 50% compared to placebo (9%) and Aricept 5mg/day (7%). The table also shows the change from baseline for each treatment group.*
Aricept-04 (Aricept 04)
This appears to be a chart or table related to a study of a medication called "icept" at a dosage of "10 mg/day," as well as another medication called "Arcept Smolday" and a placebo. The chart appears to track the percentage of patients who experienced varying degrees of improvement or decline on a "CIBIC-plus Rating." However, without more context it is difficult to provide a more specific description of the study or its findings.*
Aricept-05 (Aricept 05)
Aricept-06 (Aricept 06)
Aricept-07 (Aricept 07)
Aricept-08 (Aricept 08)
Aricept-09 (Aricept 09)
Aricept-10 (Aricept 10)
This text seems to be a table or a graph that shows clinical improvement after 31 months of drug treatment with Aricept 10 mg/day compared to placebo. However, due to the missing information and the presence of non-English characters, it is not possible to provide further details or context.*
Aricept-11 (Aricept 11)
The text represents a comparison between Aricept, a medication, and a placebo. A dosage of 10 mg per day of Aricept was administered and compared to an inactive placebo. The rest of the text seems to be a reference number or code. The chart measures an "ADCS-ADL Change from Baseline", which may indicate a comparison of cognitive function.*
Aricept-12 (Aricept 12)
Aricept-13 (Aricept 13)
The text appears to be a chart or graph displaying the cumulative percentage of patients for Aricept 23mg and Aricept 10mg. It also includes the SIB (Severe Impairment Battery) change from baseline for these patients.*
Aricept-14 (Aricept 14)
This data appears to be a table with medication dosages and patient improvement ratings, represented by percentages. The medications listed are Aricept at dosages of 23mg/day and 10mg/day. Improvement ratings are divided into five categories: Markedly improved, moderately improved, minimally improved, no change, and worse. The table also includes a CIBIC-plus rating, which is not explained in this excerpt.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
